CYT-0851 is under clinical development by Cyteir Therapeutics and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CYT-0851’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CYT-0851 overview

CYT-0851 is under development for the treatment of relapsed/refractory B-cell non-Hodgkin lymphomas such as diffuse large B-cell lymphoma, mantle cell lymphoma, relapsed/refractory chronic lymphocytic leukemia, relapsed multiple myeloma, triple negative breast cancer, ovarian cancer, recurrent squamous cell carcinoma of the head and neck, soft tissue sarcoma, human epidermal growth factor receptor 2 negative breast cancer (her2- breast cancer), human epidermal growth factor receptor 2 positive breast cancer (her2+ breast cancer), Burkitt lymphoma, small-cell lung cancer, follicular lymphoma and metastatic pancreatic cancer. It is administered orally. The drug candidate acts by targeting RAD51 and is developed based on Cyteir's platform technology.

Cyteir Therapeutics overview

Cyteir Therapeutics is a biotechnology company. It discovers, develops and commercializes synthetic lethal therapeutics for the treatment of cancer and autoimmune disease. It specializes in the development of small molecules that targets RAD51 to induce synthetic lethality in diseases with a gain-of-function in the gene activation-induced cytidine deaminase (AID). The company focuses on providing treatments for solid tumors, lupus and type 1 diabetes. Cyteir Therapeutics is headquartered in Lexington, Massachusetts, the US.

For a complete picture of CYT-0851’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.